Literature DB >> 9573115

Identification and characterization of heparin binding regions of the Fim2 subunit of Bordetella pertussis.

C A Geuijen1, R J Willems, P Hoogerhout, W C Puijk, R H Meloen, F R Mooi.   

Abstract

Bordetella pertussis fimbriae bind to sulfated sugars such as heparin through the major subunit Fim2. The Fim2 subunit contains two regions, designated H1 and H2, which show sequence similarity with heparin binding regions of fibronectin, and the role of these regions in heparin binding was investigated with maltose binding protein (MBP)-Fim2 fusion proteins. Deletion derivatives of MBP-Fim2 showed that both regions are important for binding to heparin. The role of H2 in heparin binding was confirmed by site-directed mutagenesis in which basic amino acids were replaced by alanine. These studies revealed that Lys-186 and Lys-187 are important for heparin binding of MBP-Fim2, whereas Arg-179 is not required. Peptides derived from H1 and H2 (pepH1 and pepH2) also showed heparin binding activity. Using a series of peptides, in each of which a different basic amino acid was substituted for alanine, we demonstrated that the structural requirements for heparin binding differ significantly among pepH1 and pepH2 peptides. A Pepscan analysis of Fim2 revealed regions outside H1 and H2 which bind heparin and showed that not only basic amino acids but also tyrosines may be important for binding to sulfated sugars. A comparison of the heparin binding regions of Fim2 with homologous regions of Fim3 and FimX, two closely related but antigenically distinct fimbrial subunits, showed that basic amino acids and tyrosines are generally conserved. The major heparin binding regions identified in Fim2 are part of epitopes recognized by human antibodies, suggesting that the heparin binding regions are exposed at the fimbrial surface and are immunodominant. Since B. pertussis fimbriae show weak serological cross-reactivity, the differences in primary structure in the heparin binding regions of Fim2, Fim3, and FimX may affect antibody binding but not heparin binding, allowing the bacteria to evade antibody-mediated immunity by switching the fimbrial gene expressed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9573115      PMCID: PMC108189          DOI: 10.1128/IAI.66.5.2256-2263.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Interaction of the Bordetella pertussis filamentous hemagglutinin with heparin.

Authors:  F D Menozzi; C Gantiez; C Locht
Journal:  FEMS Microbiol Lett       Date:  1991-02       Impact factor: 2.742

2.  Description of a hybridoma bank towards Bordetella pertussis toxin and surface antigens.

Authors:  J T Poolman; B Kuipers; M L Vogel; H J Hamstra; J Nagel
Journal:  Microb Pathog       Date:  1990-06       Impact factor: 3.738

3.  Structure of the Bordetella pertussis gene coding for the serotype 3 fimbrial subunit.

Authors:  F R Mooi; A ter Avest; H G van der Heide
Journal:  FEMS Microbiol Lett       Date:  1990-01-01       Impact factor: 2.742

4.  Role of the Bordetella pertussis minor fimbrial subunit, FimD, in colonization of the mouse respiratory tract.

Authors:  C A Geuijen; R J Willems; M Bongaerts; J Top; H Gielen; F R Mooi
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

5.  Serospecific protection of mice against intranasal infection with Bordetella pertussis.

Authors:  A Robinson; A R Gorringe; S G Funnell; M Fernandez
Journal:  Vaccine       Date:  1989-08       Impact factor: 3.641

6.  Molecular modeling of protein-glycosaminoglycan interactions.

Authors:  A D Cardin; H J Weintraub
Journal:  Arteriosclerosis       Date:  1989 Jan-Feb

7.  Cloning of a novel pilin-like gene from Bordetella pertussis: homology to the fim2 gene.

Authors:  P Pedroni; B Riboli; F de Ferra; G Grandi; S Toma; B Aricò; R Rappuoli
Journal:  Mol Microbiol       Date:  1988-07       Impact factor: 3.501

8.  Characterization of fimbrial subunits from Bordetella species.

Authors:  F R Mooi; H G van der Heide; A R ter Avest; K G Welinder; I Livey; B A van der Zeijst; W Gaastra
Journal:  Microb Pathog       Date:  1987-06       Impact factor: 3.738

9.  Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes.

Authors:  F W Studier; B A Moffatt
Journal:  J Mol Biol       Date:  1986-05-05       Impact factor: 5.469

10.  Fimbrial phase variation in Bordetella pertussis: a novel mechanism for transcriptional regulation.

Authors:  R Willems; A Paul; H G van der Heide; A R ter Avest; F R Mooi
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

View more
  3 in total

Review 1.  Bordetella filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential.

Authors:  Erich V Scheller; Peggy A Cotter
Journal:  Pathog Dis       Date:  2015-09-27       Impact factor: 3.166

2.  Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease.

Authors:  Frances Alexander; Mary Matheson; Norman K Fry; Briony Labram; Andrew R Gorringe
Journal:  Clin Vaccine Immunol       Date:  2012-09-05

3.  Phase variation and microevolution at homopolymeric tracts in Bordetella pertussis.

Authors:  Emily B Gogol; Craig A Cummings; Ryan C Burns; David A Relman
Journal:  BMC Genomics       Date:  2007-05-17       Impact factor: 3.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.